 Vaxart Inc NASDAQ: VXRT is trading higher Friday after the company reported a Duke University-led study published in bioRxiv showed that the companys investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model. Vaxart said that the results are consistent with results from the companys Phase 2 human flu challenge study, which showed that Vaxarts oral tablet vaccine was better at reducing shedding than the injectable flu vaccine comparator. 